SES Logo

SYSTEMIC ENZYME SUPPORT.org

 

BehçetsBehçet’sBehçet’s

Behcet's (beh-CHETS) disease, also called Behcet's syndrome, is a rare disorder that causes chronic inflammation in blood vessels throughout your body. The signs and symptoms of Behcet's disease — which may include mouth sores, skin rashes and lesions, uveitis, and genital sores — vary from person to person and may come and go on their own. Treatment aims to reduce the signs and symptoms of Behcet's disease and to prevent serious complications, such as blindness.
Patients that did not have adequate therapeutic results from conventional therapy were started on Wobenzym® therapy, which resulted in positive results in 90% of treated patients.
                             From FREQUENTLY ASKED QUESTIONS, with answers by Joseph J Collins, RN, ND
                             Read the special section: EYES, EARS, NOSE & THROAT CONDITIONS & WOBENZYM®

What the literature says about Systemic Enzyme Support and:

Behçet’s Disease

The results of long-term use of Wobenzym in complex management of Behcet's disease.

 Kartvelishvili E., Shalamberidze L., Torondjadze M. The results of long-term use of Wobenzym in complex management of Behcet's disease. International congress "Advances in Immunology and Allergology at the Treshold of the XXI Century" May 3-6, 2000, Eilat, Israel. Center of Rheumatology, Tbilisi, Georgia [Czech abstract]

 Twenty patients (13 males and 7 females) with the confirmed diagnosis of Behcet's disease were followed-up. Average age of the patients was 41.27±2.96. The diagnosis was verified following the international criteria which were worked out by the International Study Group for Behcet's Disease (1990). As a rule each patient had recurrent aphthous stomatitis and 2 or 3 of the following four criteria: recurrent ulcers of genital organs, eye and skin lesions, positive "pathergy" test.
The patients were administered Prednisolone at a dose of 10-15 mg/day, Azathioprine (100 mg/day), non-steroid antiinammation medicines, antiaggregating drugs etc. However because of the absence of the expressed therapeutic effect after 1-1.5 months of the treatment Wobenzym (Mucos Pharma, Germany) in the dose of 7 tablets three times a day was added to the scheme. Favourable dynamics of clinical manifestations, inflammatory and immune activities were observed 0.5-1 month after introduction of Wobenzym. Significant decrease in the level of circulating immune complexes and cryoglobulins is noteworthy. Positive results (90.0%) combined with the absence of side effects and possibility to decrease the Prednisolone doses are significant success in the management of this severe disease.
Poster Reference number 23.